S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 210.5 JPY -0.05% Market Closed
Market Cap: 2T JPY
Have any thoughts about
Shionogi & Co Ltd?
Write Note

Shionogi & Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shionogi & Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
Shionogi & Co Ltd
TSE:4507
Total Current Assets
ÂĄ797.9B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
13%
Takeda Pharmaceutical Co Ltd
TSE:4502
Total Current Assets
ÂĄ3.1T
CAGR 3-Years
8%
CAGR 5-Years
5%
CAGR 10-Years
6%
Daiichi Sankyo Co Ltd
TSE:4568
Total Current Assets
ÂĄ1.9T
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
7%
Otsuka Holdings Co Ltd
TSE:4578
Total Current Assets
ÂĄ1.4T
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
2%
Chugai Pharmaceutical Co Ltd
TSE:4519
Total Current Assets
ÂĄ1.3T
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
10%
Astellas Pharma Inc
TSE:4503
Total Current Assets
ÂĄ1.2T
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
2%
No Stocks Found

Shionogi & Co Ltd
Glance View

Market Cap
1.9T JPY
Industry
Pharmaceuticals

In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.

Intrinsic Value
2 171.28 JPY
Overvaluation 2%
Intrinsic Value
Price
S

See Also

What is Shionogi & Co Ltd's Total Current Assets?
Total Current Assets
797.9B JPY

Based on the financial report for Sep 30, 2024, Shionogi & Co Ltd's Total Current Assets amounts to 797.9B JPY.

What is Shionogi & Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
13%

Over the last year, the Total Current Assets growth was -1%. The average annual Total Current Assets growth rates for Shionogi & Co Ltd have been 11% over the past three years , 11% over the past five years , and 13% over the past ten years .

Back to Top